medcelerator
Subscribe

Latest

Every verified treatment and trial we have published, newest first. Filter by country, access level, or patient stories.
All countriesUnited StatesCanadaUnited KingdomJapanChinaAustraliaSwitzerlandEuropean UnionNewestPatient StoriesEMA Authorised ×
EMA AuthorisedEuropean Union

First EU Medicine for Early Brain ALD in Boys Ages 2–12

Nezglyal (leriglitazone) — oral suspension for early cerebral adrenoleukodystrophy (Gd-negative)

EC marketing authorisation 21 Sep 2026 under exceptional circumstances; first pharmacological cALD door in the EU

This is for boys aged 2 to 12 with early cerebral adrenoleukodystrophy (cALD) — Gd-negative brain lesions on…